TLDR: Shanghai-based United Imaging Intelligence, a leading medical AI solutions provider, has successfully closed a Series A financing round, raising 1 billion yuan (approximately $139.1 million). The funding, co-led by E Fund Private Fund Management and Shanghai Guotou Investment, will primarily fuel the integration of large language models into clinical settings and the development of multi-modal medical intelligent agents, reinforcing the company’s position in the rapidly evolving healthcare AI landscape.
Shanghai United Imaging Intelligence Healthcare Co., Ltd. (United Imaging Intelligence or UII), a prominent player in medical artificial intelligence solutions, announced the successful completion of its Series A financing round, securing a substantial 1 billion yuan (approximately $139.1 million). The funding round, which closed on June 20, 2025, values the company at a pre-money valuation of 9 billion yuan (approximately $1.3 billion).
The Series A round was co-led by E Fund Private Fund Management Co., Ltd., one of China’s largest mutual fund managers, and Shanghai Guotou Investment (Shanghai Sitoco Assets Management), a subsidiary of the state-owned Shanghai International Group (SIG). Additional significant contributions came from a consortium of investors including Shanghai United Investment, Shengshi Capital, Suzhou Venture Capital Group, Junwei Venture Capital, Qingsong Capital, Zhangjiagang Venture Capital, Sun Rock Capital, Baofeng Investment, Lianzhuang Group, Lianzhuang Medical, and the parent firm, United Imaging Healthcare Technology Group. Post-financing, United Imaging Healthcare Technology Group remains the largest shareholder, holding approximately 24.1% stake in UII.
Established in December 2017, United Imaging Intelligence has rapidly emerged as a full-stack and full-spectrum medical imaging AI firm in China. The company specializes in developing advanced artificial intelligence systems aimed at clinical diagnostics and optimizing medical workflows. The newly acquired capital is earmarked to accelerate the integration of large language models (LLMs) into clinical settings and to further the development of multi-modal medical intelligent agents.
UII’s platform is designed to provide comprehensive, integrated intelligent solutions across various medical scenarios and diseases, empowering clinics, scientific research, and medical equipment with AI capabilities. Their offerings span hospital-level management, medical innovation ecology, workflow optimization, accurate diagnosis and treatment, and personal health management.
The company boasts an impressive portfolio of over 100 medical AI products, with dozens having received certifications from the NMPA (China), U.S. FDA, and EU CE, demonstrating their recognition in both domestic and international markets. In April 2025, United Imaging Intelligence unveiled its ‘Yuanzhi’ medical model, which integrates text, speech, vision, image, and hybrid modalities. This launch was accompanied by more than 10 uAI ‘Yuanzhi’ medical intelligent products, including specialized solutions for Diagnostic Intelligence, Surgical Intelligence, Service Intelligence, and Management Intelligence. Earlier innovations include the uAI Smart Chest X-ray Assistant, uAI Mammo Risk Assessment, and intelligent medical imaging devices like uCT 528 and Intelligent Digital PET-CT.
Also Read:
- China Unveils ‘Agent Hospital’: A Virtual Healthcare Revolution Powered by AI
- Chinese AI Agents Surge in 2025: A Deep Dive into Their Capabilities and Global Impact
This significant investment underscores the growing confidence in AI’s transformative potential within the healthcare sector and positions United Imaging Intelligence at the forefront of medical AI innovation, aligning with the broader trend of Chinese firms pushing the boundaries of AI advancements.
